Biofrontera AG (BFRA) and Galapagos NV (NASDAQ:GLPG) Contrasting side by side

This is therefore a comparing of the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation in Biofrontera AG (NASDAQ:BFRA) and Galapagos NV (NASDAQ:GLPG). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biofrontera AG N/A 0.00 N/A -0.76 0.00
Galapagos NV N/A 0.00 N/A -1.69 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Biofrontera AG and Galapagos NV.

Profitability

Table 2 shows Biofrontera AG and Galapagos NV’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biofrontera AG 0.00% 0% 0%
Galapagos NV 0.00% 0% 0%

Analyst Ratings

The next table highlights the given recommendations and ratings for Biofrontera AG and Galapagos NV.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Biofrontera AG 0 0 0 0.00
Galapagos NV 0 0 6 3.00

On the other hand, Galapagos NV’s potential upside is 32.79% and its consensus target price is $131.17.

Insider and Institutional Ownership

Institutional investors held 2.04% of Biofrontera AG shares and 17.2% of Galapagos NV shares. Insiders held 0.04% of Biofrontera AG shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Biofrontera AG -4.8% 5.22% -12.46% -8.79% 0% 3.25%
Galapagos NV 4.03% 0.08% 1.96% -1.78% 0.13% 11.97%

For the past year Biofrontera AG was less bullish than Galapagos NV.

Summary

Galapagos NV beats on 2 of the 3 factors Biofrontera AG.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.